GlassScriptPhysician profile
Catherine Ezell
NPI 1144831322
$1,913.69
in general payments reported to CMS, 2019-2025
27 companies · $34.90 in 2025
The $34.90 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,181 · 2022: $297 · 2023: $189 · 2024: $212 · 2025: $34.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $263.11 | 2021-2024 | Xospata |
| Janssen Biotech, INC. | $191.46 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $146.37 | 2021-2023 | Imbruvica |
| Novo Nordisk INC | $140.42 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $136.28 | 2021-2023 | Mounjaro |
| Pfizer INC. | $125.27 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $117.71 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $105.39 | 2021 | |
| Abbvie INC. | $90.81 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.41 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $54.87 | 2021 | |
| Merck Sharp & Dohme LLC | $54.43 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Melinta Therapeutics, LLC | $44.63 | 2022 | |
| Scilex Pharmaceuticals INC. | $41.39 | 2022 | |
| Genzyme Corporation | $39.46 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $35.76 | 2021 | |
| Organon LLC | $35.18 | 2024 | |
| Karyopharm Therapeutics INC. | $33.42 | 2021 | |
| Amgen INC. | $26.79 | 2021 | |
| Dova Pharmaceuticals | $24.92 | 2021 | |
| Rigel Pharmaceuticals, INC. | $24.57 | 2021 | |
| Gilead Sciences, INC. | $23.36 | 2023 | |
| Medtronic, INC. | $20.08 | 2022 | |
| Irhythm Technologies, INC. | $17.98 | 2024 | Zio Monitor, Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $17.57 | 2021 | |
| Emd Serono, INC. | $17.24 | 2021 | |
| Myovant Sciences INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Ezell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.